Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT01831089
Title	Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors
Recruitment	Completed
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	PharmaMar
Indications	head and neck cancer breast cancer ovarian cancer female reproductive organ cancer lung non-small cell carcinoma lung small cell carcinoma
Therapies	Bevacizumab + Lurbinectedin + Paclitaxel Lurbinectedin + Paclitaxel
Age Groups:	adult \| senior
Covered Countries	USA \| ESP \| CHE

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field